◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

和元生物

和元生物
Loading...
Key Metrics
Market Cap
4.5B ($649.5M)
P/E Ratio
N/A
P/B Ratio
N/A
Revenue
248.0M
Net Income
-322.0M
Gross Margin
N/A
Op. Margin
-125.0%
Net Margin
-129.8%
ROE
-18.5%
ROA
-14.1%
D/E
0.31
Dividend Yield
N/A
EPS
-0.50
Current Ratio
2.09
Price History
Company Info
IndustryM73研究和试验发展
Market SegmentSTAR Market
CurrencyCNY
Fiscal Year2024
Business Overview

Shanghai Obio Technology (Group) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and clinical trials. It also provides CDMO services encompassing process development, analytical methods, IND-enabling chemistry, manufacturing, ...

Peers
工商银行
601398
2.7T
P/E: 7.6
建设银行
601939
2.5T
P/E: 7.2
农业银行
601288
2.4T
P/E: 8.7
中国海油
600938
2.0T
P/E: 16.2
宁德时代
300750
1.9T
P/E: 25.6
贵州茅台
600519
1.8T
P/E: 20.1
中国银行
601988
1.8T
P/E: 7.3
中国人寿
601628
1.2T
P/E: 6.9
Financial Statements
Loading financials...
Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 和元生物

Shanghai Obio Technology (Group) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and clinical trials. It also provides CDMO services encompassing process development, analytical methods, IND-enabling chemistry, manufacturing, and controls; and clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products. The company was formerly known as Obio Technology (Shanghai) Corp., Ltd. and change its name to Shanghai Obio Technology (Group) Corp., Ltd. in March 2026. The company was founded in 2013 and is headquartered in Shanghai, China.


Ticker688238
ExchangeSSE
Sector证监会行业分类
IndustryM73研究和试验发展
NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...